Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous PBMC Transplantation for ALS Safety Analysis
NCT03085706Completed
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Oct 2010
- Primary completion
- Dec 2012
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of autologous G-CSF mobilized peripheral blood mononuclear cells in amyotrophic lateral sclerosis (ALS), sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoint: Adverse events of autologous peripheral blood mononuclear cell mobilization at 1 week. Started Oct 2010; status: completed.
02
Drugs
autologous G-CSF mobilized peripheral blood mononuclear cells
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03085706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03085706.